Subunit Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
Subunit Vaccine Trends and Forecast
The future of the global subunit vaccine market looks promising with opportunities in the infectious disease, diphtheria, tetanus and pertussis (DTP), HPV, measles, and mumps & rubella (MMR) markets. The global subunit vaccine market is expected to reach an estimated $2.4 billion by 2030 with a CAGR of 10.5% from 2024 to 2030. The major drivers for this market are rising demand for immunization and better safety vaccines and growing prevalence of infectious diseases.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Subunit Vaccine by Segment
The study includes a forecast for the global subunit vaccine by product type, disease, and region.
Subunit Vaccine Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:
- Protein Antigen
- Polysaccharide Antigen
Subunit Vaccine Market by Disease [Shipment Analysis by Value from 2018 to 2030]:
- Infectious Disease
- Diphtheria
- Tetanus and Pertussis (DTP)
- HPV
- Measles
- Mumps and Rubella (MMR)
- Others
Subunit Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
List of Subunit Vaccine Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies subunit vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the subunit vaccine companies profiled in this report include-
- GE Healthcare Life Sciences
- GlaxoSmithKline
- Merck
- Reber Genetics
- Sanofi
- Algenex
- Astellas Pharma
Subunit Vaccine Market Insights
Lucintel forecasts that protein will remain the larger segment due to its widespread availability and adoptability of protein antigen subunit vaccines.
North America will remain the largest region due to the high prevalence of infectious diseases in this region.
Features of the Global Subunit Vaccine Market
Market Size Estimates: Subunit vaccine market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Subunit vaccine market size by product type, disease, and region in terms of value ($B).
Regional Analysis: Subunit vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different product types, diseases, and regions for the subunit vaccine market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the subunit vaccine market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q.1 What is the subunit vaccine market size?
Answer: The global subunit vaccine market is expected to reach an estimated $2.4 billion by 2030.
Q.2 What is the growth forecast for subunit vaccine market?
Answer: The global subunit vaccine market is expected to grow with a CAGR of 10.5% from 2024 to 2030.
Q.3 What are the major drivers influencing the growth of the subunit vaccine market?
Answer: The major drivers for this market are rising demand for immunization and better safety vaccines and growing prevalence of infectious diseases.
Q4. What are the major segments for subunit vaccine market?
Answer: The future of the subunit vaccine market looks promising with opportunities in the infectious disease, diphtheria, tetanus and pertussis (DTP), HPV, measles, and mumps & rubella (MMR) markets.
Q5. Who are the key subunit vaccine market companies?
Answer: Some of the key subunit vaccine companies are as follows:
- GE Healthcare Life Sciences
- GlaxoSmithKline
- Merck
- Reber Genetics
- Sanofi
- Algenex
- Astellas Pharma
Q6. Which subunit vaccine market segment will be the largest in future?
Answer: Lucintel forecasts that protein will remain the larger segment due to its widespread availability and adoptability of protein antigen subunit vaccines.
Q7. In subunit vaccine market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region due to the high prevalence of infectious diseases in this region.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the subunit vaccine market by product type (protein antigen and polysaccharide antigen), disease (infectious disease, diphtheria, tetanus and pertussis (DTP), HPV, measles, mumps and rubella (MMR), and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Please note: It will take 2-3 business days to deliver the report upon receipt the order.